{
    "Rank": 798,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT06001099",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "RSCD2021002"
                },
                "Organization": {
                    "OrgFullName": "Fudan University",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale Cancers, PERCEIVEII",
                "OfficialTitle": "Gynecological Malignancies Earlystage Detection by Multi-omics Based Liquid Biopsy in Peripheral Blood: a Prospective, Extended Validation Study"
            },
            "StatusModule": {
                "StatusVerifiedDate": "August 2023",
                "OverallStatus": "Recruiting",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "February 22, 2023",
                    "StartDateType": "Actual"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "June 30, 2024",
                    "PrimaryCompletionDateType": "Anticipated"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "December 31, 2024",
                    "CompletionDateType": "Anticipated"
                },
                "StudyFirstSubmitDate": "August 14, 2023",
                "StudyFirstSubmitQCDate": "August 14, 2023",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "August 21, 2023",
                    "StudyFirstPostDateType": "Actual"
                },
                "LastUpdateSubmitDate": "August 14, 2023",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "August 21, 2023",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Zhong Zheng MD",
                    "ResponsiblePartyInvestigatorTitle": "Department of Gynecological Oncology, Fudan University Shanghai Cancer Center",
                    "ResponsiblePartyInvestigatorAffiliation": "Fudan University"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Fudan University",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "Guangzhou Burning Rock Dx Co., Ltd.",
                            "CollaboratorClass": "INDUSTRY"
                        }
                    ]
                }
            },
            "OversightModule": {
                "IsFDARegulatedDrug": "No",
                "IsFDARegulatedDevice": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "This study is a prospective study aimed to validate the performance of combined multi-omitcs assays for early detection of gynecologic cancers. Biomarkers of cfDNA methylation, ctDNA mutation and blood miRNA markers will be evaluated. The study will enroll approximately 2935 female participants, including participants with gynecologic cancers patients and healthy participants."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Gynecologic Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "gynecologic cancer",
                        "early detection",
                        "liquid biopsy",
                        "cell-free DNA"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Observational",
                "PatientRegistry": "No",
                "DesignInfo": {
                    "DesignObservationalModelList": {
                        "DesignObservationalModel": [
                            "Case-Control"
                        ]
                    },
                    "DesignTimePerspectiveList": {
                        "DesignTimePerspective": [
                            "Prospective"
                        ]
                    }
                },
                "BioSpec": {
                    "BioSpecRetention": "Samples With DNA",
                    "BioSpecDescription": "Plasma, white blood cells"
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "2935",
                    "EnrollmentType": "Anticipated"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Cancer arm",
                            "ArmGroupDescription": "Participants with new diagnosis of gynecologic cancers, from whom blood samples will be collected"
                        },
                        {
                            "ArmGroupLabel": "Healthy arm",
                            "ArmGroupDescription": "Participants without a known cancer or certain benign disease, from whom blood samples will be collected"
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "To validate the sensitivity, specificity and accuracy of tissue traceability of an early detection model based on combined cfDNA methylation and serum tumor markers in patients with gynecological malignancies",
                            "PrimaryOutcomeTimeFrame": "24 months"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "To verify the sensitivity, specificity and tissue traceability accuracy of cfDNA methylation as an early detection model for gynecological malignancies.",
                            "SecondaryOutcomeTimeFrame": "24months"
                        },
                        {
                            "SecondaryOutcomeMeasure": "To verify the sensitivity and specificity of serum tumor markers alone as an early detection model for gynecological malignant tumors",
                            "SecondaryOutcomeTimeFrame": "24months"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria for Cancer Arm Participants:\n\nAge 18 years or older\nAble to provide a written informed consent\nConfirmed diagnosis or highly suspicious cases of gynecologic malignancies within 42 days prior to blood collection\nNo prior or ongoing anti-cancer therapy (local or systematic) prior to study blood draw\n\nExclusion Criteria for Cancer Arm Participants:\n\nPregnancy or lactating women\nRecipients of organ transplant or prior non-autologous (allogeneic) bone marrow transplant or stem cell transplant\nRecipients of blood transfusion within 7 days prior to study blood draw\nRecipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancer.\nprevious history of malignant tumor;\nprecancerous lesions or benign diseases confirmed by biopsy or surgical specimen;\nunknown or insufficient to determine the nature of the lesion by histopathological reports;\n\nInclusion Criteria for healthy control Arm Participants:\n\nAble to provide a written informed consent.\nAble to provide sufficient and qualified blood samples for study tests.\nNo cancer related symptoms within 30 days prior to study screening.\nCancer history with curative treatment completed over 3 years without recurrence prior to study enrollment.\n\nExclusion Criteria for healthy control Arm Participants:\n\nInsufficient qualified blood sample for study test.\nDuring pregnancy or lactation.\nRecipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant.\nRecipient of blood transfusion within 30 days prior to study blood draw.\nRecipient of anti-infectious therapy within 14 days prior to study blood draw.\nHave received or are undergoing curative cancer treatment within three years prior to study screening.\nWith autoimmune or other diseases with severe comorbidities.",
                "HealthyVolunteers": "Accepts Healthy Volunteers",
                "Gender": "Female",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                },
                "StudyPopulation": "Eligible participants will be recruited from the participating medical center and assigned into two arms, including participants with new diagnosis of gynecologic malignancies and healthy controls",
                "SamplingMethod": "Non-Probability Sample"
            },
            "ContactsLocationsModule": {
                "CentralContactList": {
                    "CentralContact": [
                        {
                            "CentralContactName": "Hao Wen, MD.&PHD",
                            "CentralContactRole": "Contact",
                            "CentralContactPhone": "+86-021-64175590",
                            "CentralContactPhoneExt": "81007",
                            "CentralContactEMail": "wenhao_fdc@163.com"
                        },
                        {
                            "CentralContactName": "Yuzi Zhang, MD",
                            "CentralContactRole": "Contact",
                            "CentralContactPhone": "+86-021-60293798",
                            "CentralContactEMail": "Z_Zhangyuzi@163.com"
                        }
                    ]
                },
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Xiaohua Wu, MD.&PHD",
                            "OverallOfficialAffiliation": "Department of Gynecological Oncology, Fudan University Shanghai Cancer Center",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Fudan university shanghai cancer center, Deparment of gynecologic oncology",
                            "LocationStatus": "Recruiting",
                            "LocationCity": "Shanghai",
                            "LocationState": "Shanghai",
                            "LocationZip": "200032",
                            "LocationCountry": "China",
                            "LocationContactList": {
                                "LocationContact": [
                                    {
                                        "LocationContactName": "Hao Wen, MD.&PHD",
                                        "LocationContactRole": "Contact",
                                        "LocationContactPhone": "+86-021-64175590",
                                        "LocationContactPhoneExt": "81007",
                                        "LocationContactEMail": "wenhao_fdc@163.com"
                                    },
                                    {
                                        "LocationContactName": "Yuzi Zhang, M.D",
                                        "LocationContactRole": "Contact",
                                        "LocationContactPhone": "+86-021-60293798",
                                        "LocationContactEMail": "Z_Zhangyuzi@163.com"
                                    },
                                    {
                                        "LocationContactName": "Xiaohua Wu, MD.&PHD",
                                        "LocationContactRole": "Principal Investigator"
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "IPDSharingStatementModule": {
                "IPDSharing": "No"
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            }
        }
    }
}